VRT.CN - Veritas Pharma Inc.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.4250
+0.0350 (+8.97%)
As of 9:30AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.3900
Open0.4250
Bid0.3650 x 0
Ask0.4250 x 0
Day's Range0.4250 - 0.4250
52 Week Range0.3200 - 4.1500
Volume1,100
Avg. Volume6,859
Market Cap5.167M
Beta (3Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-1.4900
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswirelast month

    Veritas Announces Restructuring of Cannevert Therapeutics Ltd.

    VANCOUVER, British Columbia, May 15, 2019 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has undertaken steps.

  • GlobeNewswirelast month

    Veritas Announces the Completion of Clinical Trial on their Cannabis Product for Treatment of Acute Pain

    SAN JUAN, Puerto Rico, May 15, 2019 -- Veritas Pharma Puerto Rico, Inc., a wholly owned subsidiary of Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP).

  • GlobeNewswire3 months ago

    Veritas Pharma Provides Corporate Update

    2018 and the first quarter of 2019 has been a transition period for Veritas Pharma, as the company has matured from being purely engaged in research and development to establishing a viable option for cannabis production in Canada, setting the stage for potential commercialization given positive clinical trial results on its lead pain treatment and appointing new leadership to the company.

  • GlobeNewswire3 months ago

    Veritas Pharma to Commence Legal Proceedings Against Liht Cannabis

    VANCOUVER, British Columbia, March 04, 2019 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has filed a claim.

  • GlobeNewswire4 months ago

    Veritas Enrolls First Patient in Clinical Study to Assess Pain Control with Lead Product

    CTL-X, supplied by one of Puerto Rico’s notable cannabis performers, the Institute for Medical Cannabis (“IMC”), will be evaluated on its analgesic properties on simulated pain using standardized pain scales. The clinical research organization, Fundación de Investigación (“FDI”), administered the trial drug in the phase II-III unit at their state-of-the-art facility.

  • GlobeNewswire4 months ago

    Veritas Pharma Enters into agreement to acquire Commercial Hemp and Cannabis Processing Facility

    Veritas’ director, Nick Standish, commented, “this is an exciting development for Veritas as it further develops our ability to commercialize our proprietary hemp and cannabis products, in addition to expanding our production potential to topical creams and edibles along with oil extracts.

  • GlobeNewswire4 months ago

    Veritas Pharma Announces the Resignation of CEO, Dr. Lui Franciosi

    Dr. Franciosi stated, “It has been a challenging year with the regulatory delays in starting the Puerto Rico human study of CTL-X and the need to raise funds for medical cannabis research.  I am pleased to see the study approval has finally come through and that potential funding for Cannevert’s important scientific work has been secured, which means that the Veritas and Cannevert are now set for growth under new leadership. Mr. McFadden stated, “The Veritas Board would like to thank Lui for his commitment to investors and to advancing the science behind medical cannabis.”  Dr. Franciosi will continue to assist both companies in an operational capacity.

  • GlobeNewswire4 months ago

    Veritas leads Puerto Rico partnership with approval of new Investigation License

    IMC and FDI represent two of Puerto Rico’s leading researchers in medicinal cannabis. The concession is also the first of its kind, representing the first collaboration of such by local partners and a foreign-owned and publicly-traded entity.

  • GlobeNewswire4 months ago

    Veritas Pharma to Proceed with Share Consolidation

    VANCOUVER, British Columbia, Feb. 04, 2019 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it is proceeding with a.

  • GlobeNewswire5 months ago

    Veritas Pharma Signs MOU with Santa Marta Gold Holdings for a Medical Cannabis Research Collaboration

    Under the terms of the MOU, both companies wish to collaborate in a structured, scientific manner with respect to formally identifying and cooperating on the advancement of medical cannabis strains or cultivars as well as to jointly develop, commercialize and patent protect medicinal products to treat specific diseases and chronic conditions. Veritas’ CEO, Dr. Lui Franciosi stated, “Santa Marta will enable the scientists at Cannevert Therapeutics Ltd. (“CTL”) to obtain a variety of cannabis strains in the near future with the aim of discovering and developing proprietary products that have consistent and optimal clinical effects.  This will be another example of a great partnership for the science and business of medical cannabis”.

  • GlobeNewswire6 months ago

    Veritas Pharma Makes Strategic Investment in Cannabis Production for Future Cannevert R&D Needs

    VANCOUVER, British Columbia, Dec. 21, 2018 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that the.

  • GlobeNewswire6 months ago

    Veritas Appoints Corporate Secretary & CFO; and Issues Stock Options

    Blair is a corporate lawyer with many years of experience working with public companies, particularly in the cannabis industry. Blair is excited to help ensure the continued integrity of the Company’s governance framework, administration and regulatory compliance.

  • GlobeNewswire7 months ago

    Veritas Announces Binding Share Purchase Agreement with Leis Industries Limited for Sale of Sechelt Organic Marijuana

    VANCOUVER, British Columbia, Nov. 14, 2018 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has.

  • GlobeNewswire7 months ago

    Veritas Confirms Readiness for Human Trials of CTL-X for Pain; Projected to Start Early Next Month

    CTL-X is a unique cannabis strain mix which has so far demonstrated evidence of reducing acute pain. CTL-X is the culmination of two years of preclinical testing by the Company’s research arm, Cannevert Therapeutics Ltd. (“Cannevert”), located at the University of British Columbia.

  • GlobeNewswire7 months ago

    Veritas Announces First Closing of Financing

    VANCOUVER, British Columbia, Nov. 06, 2018 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce the Closing of.